The Effect of

Leeksma, AC; Derks, IAM; Kasem, MH; Kilic, E; de Klein, A; Jager, MJ; van de Loosdrecht, AA; Jansen, JH; Navrkalova, V; Faber, LM; Zaborsky, N; Egle, A; Zenz, T; Pospisilova, S; Abdel-Wahab, O; Kater, AP; Eldering, E FRONT ONCOL. 2020; 10: 609409

IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?

Leisch, M; Greil, R; Pleyer, L BRIT J HAEMATOL. 2020; 190(3): 314-317.

A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1.

Heibl, S; Buxhofer-Ausch, V; Schmidt, S; Webersinke, G; Lion, T; Piringer, G; Kuehr, T; Wolf, D; Melchardt, T; Greil, R; Thaler, J HEMATOL ONCOL. 2020; 38(5): 792-798.

Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)

Schimanski, CC; Kasper, S; Hegewisch-Becker, S; Schroder, J; Overkamp, F; Kullmann, F; Bechstein, WO; Vohringer, M; Ollinger, R; Lordick, F; Heinemann, V; Geissler, M; Schulz-Abelius, A; Bernhard, H; Schon, MR; Greil, R; Galle, P; Lang, H; Schmidtmann, I; Moehler, M ONCOIMMUNOLOGY. 2020; 9(1): 1806680

Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial

Papakonstantinou, A; Matikas, A; Bengtsson, NO; Malmstrom, P; Hedayati, E; Steger, G; Untch, M; Hubbert, L; Johansson, H; Hellstrom, M; Gnant, M; Loibl, S; Greil, R; Moebus, V; Foukakis, T; Bergh, J CANCER-AM CANCER SOC. 2020;

Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry.

Huemer, F; Weiss, L; Regitnig, P; Winder, T; Hartmann, B; Thaler, J; Piringer, G; Schmitt, CA; Eisterer, W; Gänzer, H; Wüstner, A; Andel, J; Jagdt, B; Ulmer, H; Greil, R; Wöll, E; J Clin Med. 2020; 9(4):

The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine:

Riedl, JM; Posch, F; Prager, G; Eisterer, W; Oehler, L; Sliwa, T; Wilthoner, K; Petzer, A; Pichler, P; Hubmann, E; Winder, T; Burgstaller, S; Korger, M; Andel, J; Greil, R; Neumann, HJ; Pecherstorfer, M; Philipp-Abbrederis, K; Djanani, A; Gruenberger, B; Laengle, F; Woll, E; Gerger, A THER ADV MED ONCOL. 2020; 12: 1758835919900872

Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.

Wagner, SM; Melchardt, T; Greil, R; DRUG TODAY. 2020; 56(3): 195-202.

Ribociclib-endocrine therapy (ET) combination versus chemotherapy as 1st line treatment in patients (pts) with visceral metastatic breast cancer (BC). A multicenter, randomized phase III trial: SAKK 21/18

Schwitter, M; Zaman, K; Jerusalem, G; Cazzaniga, M; Greil, R; Ursula, US; Mueller, A; Nussbaum, CU; Auteri, A; Rothgiesser, K; Dietrich, D; Ruhstaller, T CANCER RES. 2021; 81(4):

First-line treatment of hormone receptor positive metastatic breast cancer (MBC) in everyday practice: Results from the Austrian AGMT_MBC-Registry

Rinnerthaler, G; Gampenrieder, SP; Tinchon, C; Petzer, AL; Suppan, C; Heibl, S; Voskova, D; Zabernigg, AF; Egle, D; Sandholzer, M; Singer, CF; Roitner, F; Andel, J; Hubalek, M; Knauer, M; Greil, R CANCER RES. 2021; 81(4):